secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2025-02-18T23:59:59+00:00
Accession:  0000950170-25-021801
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome Q4/FY24 revenue $118.8M/$385.7M; Auvelity growth 124% YoY; Symbravo approved; pipeline NDA submissions on track
--------------------------------------------------------------------------------

- Total net product revenue FY24 $385.7M (+88%); Q4 $118.8M (+66% YoY).
- Auvelity net sales FY24 $291.4M (+124%); Q4 $92.6M (+89% YoY).
- Symbravo approved Jan 30, 2025 for acute migraine; commercial launch in ~4 months.
- Patent settlement with Teva extends Auvelity generic entry to 2038–2039; license with pediatric exclusivity.
- AXS-05 (Alzheimer's agitation) and AXS-12 (narcolepsy) NDA submissions on track for 2H 2025; AXS-14 NDA submission in 1Q 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/0000950170-25-021801-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-20250218.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-021801

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer